Business Standard

Q1 results: Sun Pharma in the black, posts Rs 1,444-crore profit

Revenue from operations in the first quarter rose 29 per cent year-on-year and 14 per cent on a sequential basis to Rs 9,669 crore

Sun Pharma
Premium

All the main areas reported growth, except the active pharmaceutical ingredients segment, which saw a 7 per cent decline in sales.

Aneesh Phadnis Mumbai
Strong growth in domestic and US markets helped India’s largest drugmaker Sun Pharmaceutical Industries report a net profit of Rs 1,444 crore in the first quarter of this financial year.
 
In the same period a year ago, the company had posted a net loss of Rs 1,655 crore owing to a drop in revenue and exceptional expenses.
 
Revenue from operations in the first quarter rose 29 per cent year-on-year and 14 per cent on a sequential basis to Rs 9,669 crore. Domestic business, which accounted for 34 per cent of the total turnover, rose 39 per cent and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in